Inclusion Criteria

          -  Subjects must be ≥ 18 years of age at the time of signing informed consent

          -  Diagnosis of primary liver malignancy (including hepatocellular carcinoma [HCC] or
             cholangiocarcinoma) or liver metastasis from any primary solid tumor site by
             characteristic imaging findings on CT or MRI, clinical presentation, and/or pathologic
             confirmation of diagnosis.

          -  Subjects with other current or prior malignancies are eligible for this study.

          -  Patients with liver metastases must have at least one of the following clinical
             factors that may affect liver function:

               1. History of liver resection (at any time)

               2. History of cirrhosis (any cause), fatty liver disease, or hepatic insufficiency
                  due to any cause

               3. Prior radiation to the upper abdomen including radioembolization

          -  ECOG (Zubrod) Performance Status 0-2.

          -  Subjects must have a Child-Turcotte-Pugh (CTP) score ≤ 7 to be eligible.

          -  Patients who have been previously treated with non-SBRT liver directed therapies may
             be enrolled on study. At least 3 months must have elapsed between the most recent
             liver-directed therapy and study entry.

          -  Ability to provide written informed consent and HIPAA authorization

          -  Subjects with an allergy to contrast agents may be enrolled at the treating
             physician's discretion with appropriate pre-treatment and symptom management.

        Exclusion Criteria

          -  Subjects who are pregnant or planning to become pregnant during the study. Women of
             child bearing potential must have a negative pregnancy test

          -  Subjects must not have received chemotherapy within 2 weeks of planned 1st day of RT.

          -  No more than 3 lesions may be treated. The maximum sum of the diameter(s) of the
             lesion(s) must be ≤6 cm

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (or infections requiring systemic antibiotic treatment), active upper GI
             ulceration or hemorrhage, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would in
             the opinion of the investigator limit compliance with study requirements